Boston, MA – February 26, 2014 – Cooley LLP announced today that it advised Eagle Pharmaceuticals Inc. on its $50.3 million IPO. Eagle Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing injectable products, primarily in the critical care and oncology areas, using the 505(b)(2) regulatory pathway. The company now trades on the NASDAQ Global Market under the symbol "EGRX."
The Cooley corporate and securities team advising Eagle included partners Marc Recht and Miguel Vega, as well as associates David Bartholomew, Anna Jarosinski, Terren O'Connor and Chris Gerry. Critical support for the offering was provided by partners Natasha Leskovsek and Wendy Goldstein and associate Jennifer Shanley (health care regulatory); partner Thomas Welk and associates Megan Arthur and Justin Ho (compensation & benefits) and partner Kenneth Krisko and Jennifer Raab (licensing).
In 2013, Cooley's capital markets practice had a record year, advising on 60 public offerings, including 23 IPOs that raised more than $8.4 billion. Year-to-date in 2014, Cooley has advised on 24 completed public offerings, including 13 completed IPOs. Last year, Cooley attorneys also handled more than 120 M&A transactions, with an aggregate deal value of more than $12.4 billion.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has more than 750 lawyers across 11 offices in the United States and China.